title: Long-term prognostic value of elevated pentraxin 3 in patients undergoing primary angioplasty for ST-elevation myocardial infarction.
abstract: OBJECTIVE
  The prognostic value of pentraxin 3 (PTX3) has been documented in patients with acute coronary syndrome. However, its long-term prognostic value in acute ST-segment elevation myocardial infarction (STEMI) remains unclear. The aim of this study was to evaluate the prognostic value of PTX3 in patients with STEMI undergoing a primary percutaneous coronary intervention (PCI).
  
  
  METHODS
  We prospectively enrolled 499 consecutive STEMI patients undergoing primary PCI. The high-PTX3 group (n=141) was defined as having values in the third tertile (≥3.2 ng/ml) and the low-PTX3 group (n=358) included patients with values in the lower two tertiles (<3.2 ng/ml).
  
  
  RESULTS
  The patients in the high-PTX3 group were older (mean age 54.3±11.8 vs. 58.5±13.1 years, P=0.002). Higher in-hospital cardiovascular mortality and 2-year all-cause mortality rates were observed in the high-PTX3 group (9.9 vs. 2.8%, respectively, P<0.001; 21 vs. 6.2%, respectively, P<0.001). In a Cox multivariate analysis, a high admission PTX3 value (>3.2 ng/ml) was found to be an independent predictor of 2-year all-cause mortality (odds ratio: 2.3, 95% confidence interval: 1.20-4.90, P=0.025).
  
  
  CONCLUSIONS
  These results suggest that a high admission PTX3 level was associated with increased in-hospital cardiovascular mortality and 2-year all-cause mortality in patients with STEMI undergoing primary PCI.
authors.affiliation: aDepartment of Cardiology, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Center, Training and Research Hospital bDepartment of Cardiology, School of Medicine, Bezmialem Vakif University, Istanbul, Turkey.
authors.forename: Ozgur
authors.initials: O
authors.lastname: Akgul
authors.forename: Omer Faruk
authors.initials: OF
authors.lastname: Baycan
authors.forename: Umit
authors.initials: U
authors.lastname: Bulut
authors.forename: Mustafa Umut
authors.initials: MU
authors.lastname: Somuncu
authors.forename: Hamdi
authors.initials: H
authors.lastname: Pusuroglu
authors.forename: Sinem
authors.initials: S
authors.lastname: Ozyilmaz
authors.forename: Mehmet
authors.initials: M
authors.lastname: Gul
authors.forename: Ali Riza
authors.initials: AR
authors.lastname: Demir
authors.forename: Emre
authors.initials: E
authors.lastname: Yılmaz
authors.forename: Serkan
authors.initials: S
authors.lastname: Yazan
authors.forename: Uğur
authors.initials: U
authors.lastname: Kokturk
authors.forename: Ilyas
authors.initials: I
authors.lastname: Cetin
authors.forename: Huseyin
authors.initials: H
authors.lastname: Uyarel
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D015415:Biomarkers / Q000378:metabolism; D002097:C-Reactive Protein / Q000378:metabolism*; D005260:Female; D017052:Hospital Mortality; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000378:metabolism* / Q000628:therapy; D062645:Percutaneous Coronary Intervention; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D000683:Serum Amyloid P-Component / Q000378:metabolism*; D000099153:Pentraxins
chemical_list: D015415:Biomarkers; D002097:C-Reactive Protein; D000683:Serum Amyloid P-Component; D000099153:Pentraxins